AR072974A1 - Sintesis de acetato de glatiramer - Google Patents
Sintesis de acetato de glatiramerInfo
- Publication number
- AR072974A1 AR072974A1 ARP090103027A ARP090103027A AR072974A1 AR 072974 A1 AR072974 A1 AR 072974A1 AR P090103027 A ARP090103027 A AR P090103027A AR P090103027 A ARP090103027 A AR P090103027A AR 072974 A1 AR072974 A1 AR 072974A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- protective group
- glatiramer
- synthesis
- acetate
- Prior art date
Links
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 title 1
- 108010072051 Glatiramer Acetate Proteins 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 229940042385 glatiramer Drugs 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 125000006239 protecting group Chemical group 0.000 abstract 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 abstract 1
- 235000019766 L-Lysine Nutrition 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- 229930195714 L-glutamate Natural products 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 229960003767 alanine Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 abstract 1
- 150000005622 tetraalkylammonium hydroxides Chemical class 0.000 abstract 1
- 229960004441 tyrosine Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
- C07K1/064—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for omega-amino or -guanidino functions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Water Supply & Treatment (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Polyamides (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Proceso para preparar un polipéptido o una sal farmacéuticamente aceptable del mismo que comprende hacer reaccionar un polipéptido con la L-lisina protegida, que comprende L-alanina, L-tirosina, L-glutamato y L-lisina protegida con un grupo protector, con un hidroxido de tetraalquilamonio en agua para eliminar el grupo protector. Se provee además un polipéptido o una sal farmacéuticamente aceptable del mismo, elaborado a través del proceso divulgado.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18821608P | 2008-08-07 | 2008-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072974A1 true AR072974A1 (es) | 2010-10-06 |
Family
ID=41653533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103027A AR072974A1 (es) | 2008-08-07 | 2009-08-06 | Sintesis de acetato de glatiramer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8212002B2 (es) |
| EP (1) | EP2326657B1 (es) |
| JP (1) | JP2011530523A (es) |
| KR (1) | KR20110059606A (es) |
| CN (1) | CN102112485B (es) |
| AR (1) | AR072974A1 (es) |
| AU (1) | AU2009279636A1 (es) |
| BR (1) | BRPI0918718A2 (es) |
| CA (1) | CA2733500A1 (es) |
| IL (1) | IL211052A (es) |
| NZ (1) | NZ590872A (es) |
| WO (1) | WO2010017292A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2277050B2 (en) | 2008-04-16 | 2022-09-28 | Momenta Pharmaceuticals, Inc. | Analysis of amino acid copolymer compositions |
| PL2307448T3 (pl) * | 2008-08-07 | 2015-10-30 | Sigma Aldrich Co Llc | Wytwarzanie polilizyny i poliornityny o małym ciężarze cząsteczkowym z wysoką wydajnością |
| ES2523732T5 (es) | 2009-04-03 | 2023-10-23 | Momenta Pharmaceuticals Inc | Control de composiciones de copolímeros |
| WO2012114167A1 (en) * | 2011-02-24 | 2012-08-30 | Biocon Limited | Processes for the preparation of glatiramer acetate |
| GB2478837A (en) * | 2011-03-14 | 2011-09-21 | Cipla Ltd | Preparation of glatiramer |
| WO2013009864A1 (en) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Structure assessment of heterogeneous polypeptide mixtures |
| WO2013009885A2 (en) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Evaluation of copolymer diethylamide |
| US8575198B1 (en) | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
| CN104844697B (zh) * | 2014-09-26 | 2018-10-23 | 深圳翰宇药业股份有限公司 | 醋酸格拉替雷的制备方法 |
| CN105884866B (zh) * | 2015-01-26 | 2021-04-20 | 漳州未名博欣生物医药有限公司 | 格拉替雷的化学合成方法 |
| WO2019002228A1 (en) | 2017-06-26 | 2019-01-03 | Institut Pasteur | TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US6013764A (en) * | 1996-07-17 | 2000-01-11 | Ortho Pharmaceutical Corp. | Liquid phase peptide synthesis of KL-4 pulmonary surfactant |
| SI2177528T1 (sl) * | 2004-09-09 | 2012-04-30 | Teva Pharma | Postopek za pripravo zmesi trifluoroacetil glatiramer acetata z uporabo očiščene bromovodikove kisline |
| EP1797109B1 (en) * | 2004-09-09 | 2016-02-24 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| CN101044188B (zh) | 2004-10-29 | 2010-08-04 | 桑多斯股份公司 | 制备格拉太咪尔的方法 |
| ZA200705874B (en) | 2005-02-02 | 2009-04-29 | Teva Pharma | Process for producing polypeptide mixtures using hydrogenolysis |
| WO2007022193A2 (en) | 2005-08-15 | 2007-02-22 | Wai Hong Chan | Process for the preparation of copolymer-1 |
| WO2009017775A2 (en) | 2007-08-02 | 2009-02-05 | Scinopharm Taiwan Ltd. | Process for the preparation of a polypeptide |
| US8497630B2 (en) * | 2009-05-08 | 2013-07-30 | Scinopharm Taiwan Ltd. | Methods of analyzing peptide mixtures |
-
2009
- 2009-08-05 US US12/536,023 patent/US8212002B2/en not_active Expired - Fee Related
- 2009-08-05 AU AU2009279636A patent/AU2009279636A1/en not_active Abandoned
- 2009-08-05 JP JP2011522216A patent/JP2011530523A/ja active Pending
- 2009-08-05 NZ NZ590872A patent/NZ590872A/xx not_active IP Right Cessation
- 2009-08-05 CA CA2733500A patent/CA2733500A1/en not_active Abandoned
- 2009-08-05 EP EP09805500.7A patent/EP2326657B1/en not_active Not-in-force
- 2009-08-05 BR BRPI0918718A patent/BRPI0918718A2/pt not_active Application Discontinuation
- 2009-08-05 KR KR1020117005133A patent/KR20110059606A/ko not_active Withdrawn
- 2009-08-05 CN CN2009801308021A patent/CN102112485B/zh not_active Expired - Fee Related
- 2009-08-05 WO PCT/US2009/052845 patent/WO2010017292A1/en not_active Ceased
- 2009-08-06 AR ARP090103027A patent/AR072974A1/es unknown
-
2011
- 2011-02-03 IL IL211052A patent/IL211052A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009279636A1 (en) | 2010-02-11 |
| US20100036092A1 (en) | 2010-02-11 |
| BRPI0918718A2 (pt) | 2015-12-01 |
| CA2733500A1 (en) | 2010-02-11 |
| CN102112485A (zh) | 2011-06-29 |
| US8212002B2 (en) | 2012-07-03 |
| JP2011530523A (ja) | 2011-12-22 |
| EP2326657B1 (en) | 2017-09-27 |
| IL211052A0 (en) | 2011-04-28 |
| EP2326657A4 (en) | 2012-10-31 |
| CN102112485B (zh) | 2013-11-27 |
| NZ590872A (en) | 2012-10-26 |
| KR20110059606A (ko) | 2011-06-02 |
| IL211052A (en) | 2016-05-31 |
| EP2326657A1 (en) | 2011-06-01 |
| WO2010017292A1 (en) | 2010-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072974A1 (es) | Sintesis de acetato de glatiramer | |
| UA113165C2 (xx) | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| BR112013000920A2 (pt) | compostos para a redução de produção de beta-amiloide | |
| BR112013025881A2 (pt) | composto representado pela fórmula geral (i), composto ou um sal do mesmo, inibidor deagregação tau, inibidor de b-secretase, inibidor de agregação de b-proteína amiloide, composição farmacêutica, preparação oral ou parenteral e composto representado pela fórmula geral (ii) | |
| AR093705A1 (es) | Depsipeptido y sus usos | |
| TW200801035A (en) | Peptide vaccine for producing anti-amyloid beta peptide antibody | |
| MX359680B (es) | Vacunas peptídicas para cánceres que expresan antígenos hig2 asociados con tumores. | |
| AR089268A1 (es) | Composiciones acuosas para el cuidado bucal | |
| AR079706A1 (es) | Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso | |
| AR077629A1 (es) | Mimetico de smac | |
| GB0914287D0 (en) | Compositions | |
| ES2721900T3 (es) | Polvo y suspensión acuosa de liberación prolongada que comprende metilfenidato | |
| EA201600442A1 (ru) | Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол | |
| SI2150538T1 (sl) | Novi substituirani hidantoini | |
| CY1118036T1 (el) | Βελτιστοποιημενη συνθεση καθαρων μη-πολυμορφικων, κρυσταλλικων χολικων οξεων με καθορισμενο μεγεθος σωματιδιων | |
| IN2012DN00765A (es) | ||
| NZ593524A (en) | A nonapeptide with anti-tumour activity | |
| AR074545A1 (es) | Proceso de preparacion de dihidroetorfina | |
| AR048954A1 (es) | Proceso para la preparacion de telmisartan. composiciones farmaceuticas | |
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| WO2012159027A3 (en) | Osw-1 analogs and conjugates, and uses thereof | |
| AR083766A1 (es) | Peptido inmunogenico | |
| WO2009072555A1 (ja) | 癌ワクチン | |
| SI2200981T1 (sl) | Novi derivati karbamoilglicina | |
| ES2571217T3 (es) | Profármacos de sitagliptina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |